Barr Announces Reorganization of Senior Management, Business...(ed Chief Executive Officer Duramed Pharm...),Health

Fred Wilkinson has been named to the newly created position of Chief Executive Officer of Duramed Pharmaceuticals, Barr's proprietary products business, with responsibility for all functions related to product selection, clinical development, and sales and marketing. He will also continue directing Barr's growing global biologics development program. In addition, Wilkinson will assume responsibility for the strategic direction and coordination of the Company's global business development activities for our generic, proprietary and biologics activities.

Wilkinson joined the Company in 2006, bringing more than 25 years of experience to Duramed. Prior to joining Duramed Pharmaceuticals, he served as Chief Executive Officer, President and a member of the Board of Directors of Columbia Laboratories from 2001. From 1996 to 2001, Wilkinson served as Watson Pharmaceuticals' Chief Operating Officer and Senior Vice President. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility.

Bogda Named President and Chief Operating Officer, Barr Laboratories, Inc.

Mike Bogda has been named President and Chief Operating Officer of Barr Laboratories, Inc. In his new position, Bogda will continue to oversee all aspects of GPS and his responsibilities will be expanded to include Quality and Pharma Chemicals. In addition to his operational oversight responsibilities, Bogda will also have increased responsibility in the Company's budgeting, financial forecasting and capital management activities. Bogda will report directly to Mundkur.

Bogda joined Barr in 2000 as Vice President of Validation and Technical Services and has held positions of increasing responsibility. He was promoted to Senior Vice President, Manufacturing and Engineering in 2001, and most recently served as Executive Vice President, Global Pro
'/>"/>